Capivasertib Cost-Effectiveness in Advanced Bre...

By Rene Pretorius

April 18, 2025

Capivasertib, a novel AKT inhibitor, has gained approval as a second-line therapy for advanced breast cancer, but its high cost has sparked concerns about ...
Sugary Drinks Cancer Risk: Women Face Higher Oral Cavity Cancer Threat
Neoadjuvant Immunotherapy Efficacy: Enhancing Treatment Strategies for Head a...
Enhancing UK Clinical Trials Inclusivity: Opportunities and Innovations in Me...
Toripalimab Evidence Journey in Cancer Care
Approval of Pembrolizumab Enfortumab Therapy: Insights on Efficacy, Costs, an...
Cancer Control Month 2025: Key Takeaways from President Trump’s National Call...
Tobacco Head Neck Cancer: Unraveling Mutational Signatures and Prevention Str...
Oral Cancer in East Africa: The Need for Early Detection
HPV Testing in Head and Neck Squamous Cell Carcinoma
Oral Health in Africa: Promoting Collaborative Solutions
Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implic...
Advances in Colorectal Cancer Screening: Access and Cost